Losartan potassium, an angiotensin II receptor antagonist is used in treatment of hypertension. It is readily absorbed from the GIT following oral administration with poor bioavailability experiencing extensive first pass metabolism and low elimination half-life.

The present work was aimed to control drug delivery and alter the pharmacokinetics and pharmacodynamics of Losartan potassium, to ensure safety, improve efficacy, therapeutic action as well as patient compliance. The influence of variables such as concentration of the hydrophilic and hydrophobic polymers on *in-vitro* release profiles of tablets prepared by wet granulation was determined.

Materials and Methods {#sec1-1}
=====================

Identification test for drug {#sec2-1}
----------------------------

Scanning of Losartan potassium was carried out in 0.1 N HCl and phosphate buffer (pH 6.8) using UV spectrophotometer and the plot of absorbance v/s wavelength was recorded.
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Drug excipients interaction study {#sec2-2}
---------------------------------

The spectra for the prepared samples was recorded using FTIR spectrophotometer (JASCO 460 plus) and compared with the spectrum of drug to check the chemical interaction.

Formulation of sustained release matrix tablets {#sec2-3}
-----------------------------------------------

Tablets were prepared using different ratios of hydrophilic and hydrophobic polymers along with other excipients by wet granulation method single punch tablet machine.

Evaluation of sustained release matrix tablet {#sec2-4}
---------------------------------------------

The prepared tablets were evaluated for hardness, thickness, friability, weight variation, drug content, swelling study, *in vitro* dissolution study, SEM study and stability studies.

Results and Discussion {#sec1-2}
======================

Formulation excipients were selected based upon their compatibility with the drug. IR spectra showed that there was no interaction between the drug and the excipient. The tablets prepared from HPMC K15M/K100M with increasing concentration of Eudragit RS 100 showed significant difference between the results. It was clear from *in vitro* dissolution studies that the tablet with combination of HPMC K15M and Eudragit RS 100 showed better drug release pattern as compared to other batches. The drug release for extended duration is due to the rapid diffusion of dissolved drug through the hydrophilic gel matrix and hydrophobic matrix sustaining the release of the drug.

Conclusion {#sec1-3}
==========

Losartan potassium can be formulated as a sustained release dosage form using 20% HPMC K15M with 5% Eudragit RS 100. Hydrophilic matrix of HPMC alone could not control the release of drug effectively for 12 hours and the release pattern was satisfactory. The use of Eudragit along with HPMC proved to show better retarding ability which was clearly seen from the result.\[[@ref1][@ref2]\]
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